The global pharmaceutical industry experienced a 114% rise in company filings mentions of environmental sustainability in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novozymes with 27% year-on-year increase, according to GlobalData’s analysis of over 757 pharmaceutical company filings. With an increasing focus on ESG, pharmaceutical companies are under pressure to incorporate sustainability with suppliers playing a crucial role in the process. GlobalData’s ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain report includes the ESG measures and response, and ESG ratings of pharmaceutical companies as assessed by leading ESG rating agencies. Buy the report here.
Notably, environmental sustainability was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of robotics and social, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, Novozymes had the greatest increase in references for environmental sustainability in Q1 2023, compared with the previous quarter. GlobalData identified 349 environmental sustainability-related sentences in the company's filings, an increase of 600% in Q1 2023 compared with Q4 2022. Bayer’s mentions of environmental sustainability rose by 3800% to 275 and GSK’s by 20000% to 201 and Novartis’s by 1500% to 165 and Pfizer’s by 1600% to 137.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for environmental sustainability in Q1 2023 was 107.
To further understand GlobalData's analysis on ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain, buy the report here.